Exagen Valuation
| XGN Stock | USD 4.10 0.18 4.59% |
At this time, the firm appears to be overvalued. Exagen Inc shows a prevailing Real Value of $3.04 per share. The current price of the firm is $4.1. Our model computes the value of Exagen Inc from reviewing the firm fundamentals such as Current Valuation of 70.66 M, profit margin of (0.31) %, and Operating Margin of (0.17) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Exagen's valuation include:
Price Book 5.3729 | Enterprise Value 70.7 M | Enterprise Value Ebitda (0.16) | Price Sales 1.2202 | Enterprise Value Revenue 1.2674 |
Overvalued
Today
Please note that Exagen's price fluctuation is very risky at this time. Calculation of the real value of Exagen Inc is based on 3 months time horizon. Increasing Exagen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Exagen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Exagen Stock. However, Exagen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.1 | Real 3.04 | Target 6.25 | Hype 3.92 | Naive 4.5 |
The intrinsic value of Exagen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Exagen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Exagen Inc helps investors to forecast how Exagen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Exagen more accurately as focusing exclusively on Exagen's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Exagen's intrinsic value based on its ongoing forecasts of Exagen's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Exagen's closest peers.
Exagen Cash |
|
Exagen Valuation Trend
Knowing Exagen's actual value is paramount for traders when making sound investment determinations. Using both Exagen's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Exagen Total Value Analysis
Exagen Inc is at this time forecasted to have company total value of 70.66 M with market capitalization of 69.14 M, debt of 23.72 M, and cash on hands of 76.39 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Exagen fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
70.66 M | 69.14 M | 23.72 M | 76.39 M |
Exagen Investor Information
About 30.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 0.94. Exagen Inc had not issued any dividends in recent years. Based on the analysis of Exagen's profitability, liquidity, and operating efficiency, Exagen Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Exagen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Exagen has an asset utilization ratio of 92.28 percent. This suggests that the Company is making $0.92 for each dollar of assets. An increasing asset utilization means that Exagen Inc is more efficient with each dollar of assets it utilizes for everyday operations.Exagen Ownership Allocation
Exagen holds a total of 17.64 Million outstanding shares. Over half of Exagen's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Exagen Profitability Analysis
The company reported the last year's revenue of 52.55 M. Reported Net Loss for the year was (23.69 M) with profit before taxes, overhead, and interest of 21.35 M.About Exagen Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Exagen Inc. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Exagen Inc based exclusively on its fundamental and basic technical indicators. By analyzing Exagen's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Exagen's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Exagen. We calculate exposure to Exagen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Exagen's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 29.5 M | 16.8 M | |
| Pretax Profit Margin | (0.45) | (0.47) | |
| Operating Profit Margin | (0.43) | (0.46) | |
| Net Loss | (0.45) | (0.47) | |
| Gross Profit Margin | 0.56 | 0.59 |
Exagen Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 17.7 M |
Exagen Current Valuation Indicators
Exagen's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Exagen's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Exagen, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Exagen's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Exagen's worth.When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.